As shown in Figure 1a, individual IITZ-01 (0.5, 1 μM) and TRAIL (30, 50 ng/mL) had no effect on apoptosis in human renal carcinoma (Caki-1 and ACHN) cells, but combined treatment of IITZ-01 and TRAIL remarkably increased the sub-G1 population and cleavage of PARP. This evidence concerns the gene TNFSF10 and renal carcinoma.